Research programme: HIV protease inhibitors - Abbott Laboratories
Alternative Names: A-681799; A-790742; A-792611Latest Information Update: 22 Jan 2013
At a glance
- Originator Abbott Laboratories
- Class Dipeptides; Pyridines
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
- 02 Feb 2006 Data presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2005) have been added to the Viral Infections pharmacodynamics section
- 22 Sep 2005 Data presented at the 230th American Chemical Society National Meeting (230th-ACS-2005) have been added to the pharmacokinetics section